Hot topics, news and discussions at Advanced Therapies Week 2025
Advanced Therapies Week (ATW) 2025 took place Dallas, US, from 20-23 January 2025. DDW’s Megan Thomas hears from industry experts in attendance and reports on news from the event.
Patient perspective
Michalle Adkins, Director of Life Sciences Strategy and Direction at Emerson USA, said: “One of the most exciting things about ATW is that the conference always brings the patient perspective into clearer focus. This year, I had the opportunity to speak with a number of patients impacted by modern therapies. Those conversations are a fantastic reminder of why we do what we do—the hard work of providing modern solutions to help get products to market faster.”
Adkins discussed stories like those told by Chris White, a rare melanoma survivor, patient advocate, and industry educator, who “make it clear just how important it is to employ modern technologies to make the drug development pipeline faster, more efficient, and more reliable to ensure a higher percentage of treatments are right the first time”.
In addition, Adkins found he returned regularly to a core theme of ATW 2025: data accessibility. He said: “Through those conversations, we were able to build a common understanding around the need for more open protocols like OPC UA—even in standalone pieces of equipment—to help make critical data available at higher levels to accelerate and modernise the development pipeline. This growing collaboration between laboratories, manufacturers, OEMs, CDMOs, patient advocates, and more is incredibly exciting, and the fact that it was on display front and centre at ATW speaks to the brave new world of treatment manufacturing just over the horizon.”
CGTs of the future
Lukas Kaßer, Chief Technology Officer, Green Elephant Biotech, said that making the therapies of the future available to everyone is a “universal driver”. He continued: “It was exciting to discuss current challenges in CGT upstream processes with interesting people from the industry. Integrated bioprocesses, from initial R&D to fill and finish, are needed to ensure smooth development and the shortest possible time to market.”
Part of the challenge, he says, is finding the right timing for upstream process development, building the supply and service chain, and engaging experienced and diligent partners to build quality into biopharmaceuticals from the start and ensure that quality is maintained. He concluded: “In upstream processing, skilled manual labour and cleanroom space remain major bottlenecks to manufacturing output, requiring automation, improved process control and process intensification of manufacturing facilities.”
Collaboration across clinical centres
Carol Houts, Chief Commercial and Strategy Officer at GermFree, said that ATW 2025 conversations reinforced that innovation in cell and gene therapy depends on collaboration across clinical centres, industry leaders, and advocacy groups. She said: “Discussions on centralised versus decentralised manufacturing highlighted the need for flexible solutions that balance efficiency with patient access. Clinical readiness emerged as a critical theme during the event, particularly through discussions at the Unlocking the Future: Empowering Clinical Centers to Deliver Cell Therapies workshop.”
Houts said that experts highlighted the evolving accreditation landscape, workforce training needs, and operational challenges that clinical sites face in scaling cell therapy programmes. She added that panellists, including leaders from FACT, CTMC, and major clinical centres, emphasised the importance of building capacity through accreditation models that streamline readiness, leveraging scalable modular infrastructure, and integrating process innovations to enhance efficiency.
Houts continued: “Another key theme throughout the event was leveraging existing networks—particularly the blood industry’s role in supporting CGT supply chains and clinical operations. Beyond the technical and logistical discussions, the conversation on women leading innovation in advanced therapies highlighted the importance of mentorship and diverse leadership in shaping the future of the field. These discussions underscored that progress in advanced therapies isn’t just about technology—it’s about people, partnerships, and breaking barriers together.”
Commercialisation of next-generation therapies
Stella Vnook, CEO of Likarda, said that discussions regarding the commercialisation of next-generation therapies highlighted the growing need for scalable, efficient delivery mechanisms, particularly for cell therapies targeting solid tumours. She said: “A key theme was the challenge of ensuring cell viability and controlled therapeutic release to improve patient outcomes. Experts explored how improved drug delivery and other technologies could enhance efficacy while addressing manufacturing and regulatory hurdles. The conference reinforced that the future of commercialisation lies in integrating innovative delivery platforms with robust clinical and market strategies to drive broader adoption of these transformative therapies.”
Evolving landscape of CGT manufacturing
Natalia Elizalde, Chief Business Development Officer of VIVEbiotech, said that ATW was “an exceptional platform for discussing the evolving landscape of cell and gene therapy manufacturing”. She was particularly excited to engage in conversations about the increasing demand for high-quality lentiviral vectors and the critical role of manufacturing innovation in accelerating the development of advanced therapies. She said: “A key theme was the growing emphasis on scalability and regulatory alignment to support global commercialisation efforts.”
In addition, VIVEbiotech was recognised as the CMO/CDMO of the Year at the Advanced Therapies Awards. Elizalde commented: “The receipt of this award has further reinforced our commitment to providing tailored, GMP-grade lentiviral vector solutions that meet the industry’s evolving needs. We look forward to continuing these discussions and driving innovation in advanced therapies.”
In-person collaboration
ARScience reportedly engaged in a series of meetings with multiple companies collaborating on the development of our key compounds—low dose recombinant interleukin-2 (rH IL-2) and IL-15—while also exploring cutting-edge technologies to enhance the company’s portfolio’s value in terms of market readiness and applications. Carlos Bañado, CEO, ARScience Bio, said: “Additionally, we had the opportunity to connect with several companies investigating the use of our rH IL-2 as an adjuvant in their cell therapy programs. In summary, it was a highly productive event with significant outcomes.”
Responsibility for CGT challenges
Becky Butler Cap, Senior Vice President, Biotherapies, Vitalant, said that in 2025, we find ourselves in an industry “struggling to mature”. Of the topics discussed, Butler Cap notes that even as conversations about how to make progress with fewer—and more constrained—resources intensified, discussion circled back to making room for personal and professional development and what it means to ‘have it all’. Butler Cap said: “We need to spend time nurturing our industry, taking care to evaluate where the constraints are and where those constraints are causing pain. In parallel, we must invest in our own growth, managing the needs of work and home and using all the resources available to us, to make it all work. In both the industry and in our personal/professional lives, we want it all and we want all our potential to be fulfilled. With patience and a bit of resourcefulness, it can be, but it will take time, discipline, and focus—and success will come in stages, not in one crashing wave.”
Discussing commercialisation
Josh Ludwig, Global Commercial Director, ScaleReady, said that the most interesting conversations at ATW were around commercialisation, with many discussing how to identify and avoid issues. He said: “There are a number of commonalities that many developers are experiencing, such as the desire to implement process automation early in development to reduce variability and improve scalability. Affordability is a perennial concern, and therefore lowering manufacturing costs, which requires streamlining processes.”
Given the “impossibility” of large-batch manufacturing, especially for autologous cell therapies, Ludwig said a common approach is using modular devices for cell expansion that can be scaled linearly. He commented: “We once again found ourselves urging companies in earlier stages of development to incorporate such late-stage planning as soon as possible, to smooth the transition when needed down the road.”
News from the event
Launches
- Blood and Cells Advocacy Roster (BCAR) launched to provide a single voice/think tank for a consortium of stakeholders in the CGT starting materials and blood therapy fields. The steering committee, founded by IB Communications’ Michelle Boxall, includes representatives from Association for the Advancement of Blood & Biotherapies (AABB), BioBridge Global, Blood Centers of America (BCA), OrganaBio, Terumo Blood and Cell Technologies (Terumo BCT), and Vitalant. The kick-off at ATW included a roundtable on the industry functioning as a ‘network of networks’ to solve CGT challenges.
- Charles River Laboratories rolled out the Charles River Incubator Program (CIP) to support startup and early-stage biotechs from discovery through clinical regulatory submission. The programme, which echoes Charles River’s existing Cell and Gene Therapy Accelerator Program (CAP), offers consulting expertise, training, and lab space at the company’s Global Innovation Center of Excellence (CoE) in Alderley Park, UK. It is designed as an accelerator that can position young drug developers for eventual commercial viability. Applications are now open.
- Bio-Techne Corporation presented a breakout session on closed-system CGT manufacturing. The company’s portfolio of reagents and analytical technologies, including the recently launched ProPak liquid GMP cytokines, are commonly delivered in simplified, closed processes for T cell expansion with bioreactors like Wilson Wolf’s G-Rex. This approach is applicable for both CAR T- and TCR-T-cell therapy manufacturing.
- BioBridge Global announced the launch of a new subsidiary, BBG Advanced Therapies, consolidating its CGT Services portfolio. Existing company divisions had housed an array of services including leukapheresis, testing/analytical development, biomanufacturing, tech transfer, and process development. The new unit will now offer customers a single CGT partner under Chief Operating Officer Adrienne Mendoza, formerly COO of BioBridge Global’s South Texas Blood & Tissue subsidiary.
Partnerships
- Catalent is collaborating with Galapagos NV for decentralised clinical manufacturing of the CD19 CAR T-cell therapy GLPG5101, currently in Phase I/II testing for patients with relapsed/refractory non-Hodgkin lymphoma (NHL). Catalent will support manufacturing for upcoming trials in the New York/New Jersey area from its commercial CGT manufacturing facility in Princeton (NJ). This decentralised approach can reduce median vein-to-vein time to seven days for patients suffering from an aggressive form of NHL.
- SCTbio announced a strategic partnership with CCRM Nordic to provide end-to-end manufacturing support for young CGT developers, which can now leverage SCTbio’s cGMP manufacturing expertise in a single, seamless pathway with CCRM Nordic’s analytical capabilities and infrastructure. The partners will offer services and support for Phase I/II CGT development.
- ReiThera announced its strategic partnership with Sillajen to produce the next-generation anticancer virus platform SJ-600. This global cooperation agreement (MSA) entrusts CDMO ReiThera with the task of transforming the SJ-600 series into a GMP-grade drug ready for clinical trials. This collaboration is built on ReiThera’sexpertise in developing vaccines for infectious diseases and cancer, as well as gene therapies. Having successfully contributed to vaccination campaigns against the Ebola and Marburg viruses, ReiThera now brings its advanced infrastructure and solid know-how in producing Vaccinia-lineage viruses, a key component of the SJ-600 technology.
Awards
- Phacilitate awarded Dr Katherine High the Lifetime Achievement Award for 2025 at the Advanced Therapies Awards Ceremony. Dr High’s contributions to CGTs include the clinical development of two commercial therapies, Luxturna and Beqez, as well as overcoming multiple challenges related to the clinical use of adeno-associated virus (AAV) vectors. Other Advanced Therapies Awards winners included Regeneron, VIVEbiotech, Cryoport Systems, Akadeum Life Sciences, AviadoBio, Siren Bioechnology and Forge Biologics, as well as Columbia University PhD candidate Sharifa Davis and Kudo Biotechnology’s Molly McGlaughlin.
- In parallel, Emerson received the Industrial IoT Innovation of the Year at the IoT Breakthrough Award for its DeltaV Workflow Management software. The software-as-a-service was designed as a cloud-based solution for early-stage developers to transition drug recipe workflow data from paper to digital records. The company has been recognised by the IoT Breakthrough Awards annually since 2018.
Showcases
- PHC Corporation of North America (PHCNA) showcased a prototype of its LiCellGrow Cell Expansion System at the conference, a platform with in-line monitoring capabilities for real-time monitoring and controlling of metabolic changes in the cell culture environment. LiCellGrow combines the company’s blood glucose sensor technology with advanced cell culture environmental controls. Upon its near-term launch, LiCellGrow could support the manufacture of high-quality CGT products without costly and inefficient manual sampling.
- Cardinal Health Nuclear & Precision Health Solutions (NPHS) featured its “white glove” delivery solution at the conference. NPHS offers bespoke CGT delivery support, intended to reduce friction in the supply chain from cell collections logistics that enable just-in-time delivery to kitting and supply procurement. NPHS’ network includes existing relationships with 6,600 locations and access to 95% of hospitals in three hours or less.
- Nanoscope Therapeutics presented at the JP Morgan Healthcare Conference on its progress towards a Biologics License Application (BLA) and commercialisation for its lead gene therapy, Multi-Characteristic Opsin (MCO-010), for patients with retinitis pigmentosa. The company’s next programme, an AAV-based gene therapy to treat Stargardt macular degeneration, is also advancing to Phase III testing.
